ASXL1 and acute myeloid leukemia: It has also been reported that the presence of ASXL1 and SETBP1 mutations reduces histone H3 and H4 acetylation levels near the TGFβ target gene promoter region and inactivates the TGFβ pathway, thus inhibiting AML progression (Inoue et al., 2015; Makishima et al., 2013; Saika et al., 2018).